DVAX Similar Chart Price Prediction
The price of DVAX is predicted to go up -35.74%, based on the high correlation periods with OLN. The similarity of these two price pattern on the periods is 92.26%.
DVAX
OLN
Down: -35.74%Similarity: 92.26%
DVAX Revenue Forecast
DVAX EPS Forecast
DVAX FAQs
What is bull’s view on DVAX?
What is bear's view on DVAX?
What is DVAX revenue forecast for next quarter？
DVAX Analyst's Forecast
Paul Choi
Goldman Sachs
Hold → Strong Sell
2025-02-11
Price Target
$15 → $12
Downside
-5.51%
Goldman Sachs downgraded Dynavax to Sell from Neutral with a price target of $12, down from $15. The evolving competitive landscape in shingles vaccination lowers the potential of the company's Z-1018 program and increases long-term revenue uncertainty, the analyst tells investors in a research note. In addition, the firm says " unpredictable demand patters" for repeat hepatitis-B vaccinations in the 2030s, could cloud the long term outlook for Heplisav-B beyond its peak sales despite its market share gains. Goldman says Dynavax now ranks in the lowest quintile for potential upside in its coverage group.
